Top

Published in:

01-03-2020 | Gallbladder Cancer | Original Article

Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients

Authors: Simone Conci, Andrea Ruzzenente, Michele Simbolo, Fabio Bagante, Borislav Rusev, Giulia Isa, Rita T. Lawlor, Corrado Pedrazzani, Calogero Iacono, Alfredo Guglielmi, Aldo Scarpa

Published in: Updates in Surgery | Issue 1/2020

Abstract

The aim of the present study was to investigate the relationship between the mutational gene profile and recurrence in biliary tract cancers (BTC). A total of 103 specimens of patients with BTC, who underwent curative surgery in a single tertiary HPB surgery referral center from 1990 to 2012, were assessed for mutational status in 52 cancer-related genes. Considering the different types of BTC, the 5-year recurrence-free survival (RFS) rate was 16.7% (median RFS 7 months) in gallbladder cancer, 42.9% (median RFS 26.4 months) in intrahepatic cholangiocarcinoma, and 19.7% (median RFS 16.5 months) in perihilar cholangiocarcinoma, p = 0.166. At the multivariate analysis including clinical, pathological, and molecular features, the factors independently related to RFS were radicality of surgery (OR 2.050, CI 1.104–3.807, p = 0.023), LN status (OR 1.835, CI 1.006–3.348, p = 0.048), mutational status of ARID1A (OR 2.566, CI 1.174–5.608, p = 0.018), and TP53 (OR 2.805, CI 4.432–5.496, p = 0.003). ARID1A mutation was associated with a local and systemic recurrence in the 43% and 29% of cases, respectively; and TP53 mutation was associated with a local and systemic recurrence in the 29% and 41% of cases. Moreover, TP53 was most commonly mutated in tumor of patients with early recurrence, p = 0.044. ARID1A and TP53 mutations seem to be related to poor outcome after surgery and may be considered molecular predictors of the biological aggressiveness in BTC.

Available only for authorised users

Patel T (2011) Cholangiocarcinoma—controversies and challenges. Nat Rev Gastroenterol Hepatol. 8(4):189–200. https://doi.org/10.1038/nrgastro.2011.20 CrossRefPubMedPubMedCentral

American Joint Committee on Cancer (AJCC) (2018) Cancer staging manual, 8th edn. Springer, New York

Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C (2009) Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 33:1247–1254. https://doi.org/10.1007/s00268-009-9970-0 CrossRefPubMed

Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L, Lau W, Wu M, Shen F (2013) Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 31:1188–1195. https://doi.org/10.1200/JCO.2012.41.5984 CrossRefPubMed

Gaspersz MP, Buettner S, Roos E, van Vugt JLA, Coelen RJS, Vugts J, Wiggers JK, Allen PJ, Besselink MG, Busch ORC, Belt EJ, D'Angelica MI, DeMatteo RP, de Jonge J, Kingham TP, Polak WG, Willemssen FEJA, van Gulik TM, Jarnagin WR, Ijzermans JNM, Groot KB (2018) A preoperative prognostic model to predict surgical success in patients with peri-hilar cholangiocarcinoma. J Surg Oncol 118(3):469–476. https://doi.org/10.1002/jso.25174 CrossRefPubMed

Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J (1990) Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 159:91. https://doi.org/10.1016/s0002-9610(05)80612-9 CrossRefPubMed

Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258(1):129–140. https://doi.org/10.1097/SLA.0b013e3182708b57 CrossRefPubMed

Conci S, Ruzzenente A, Sandri M, Bertuzzo F, Campagnaro T, Bagante F, Capelli P, D’Onofrio M, Piccino M, Dorna AE, Pedrazzani C, Iacono C, Gugleilmi A (2017) What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes. Eur J Surg Oncol 43(4):743–750. https://doi.org/10.1016/j.ejso.2016.12.007 CrossRefPubMed

Conci S, Ruzzenente A, Viganò L, Ercolani G, Fontana A, Bagante F, Bertuzzo F, Dore A, Pinna AD, Torzilli G, Iacono C, Guglielmi A (2018) Pattern of distribution of hepatic nodules (single, satellites or multifocal) in intrahepatic cholangiocarcinoma: prognostic impact after surgery. Ann Surg Oncol 25(12):3719–3727. https://doi.org/10.1245/s10434-018-6669-1 CrossRefPubMed

10.

Ruzzenente A, Conci S, Viganò L, Ercolani G, Manfreda S, Bagante F, Ciangherotti A, Pedrazzani C, Pinna AD, Iacono C, Torzilli G, Guglielmi A (2019) Role of Lymph node dissection in small (%3c3cm) intrahepatic cholangiocarcinoma. J Gastrointest Surg 23(6):1122–1129. https://doi.org/10.1007/s11605-019-04108-0 CrossRefPubMed

11.

Creasy JM, Goldman DA, Gonen M, Dudeja V, O’Reilly EM, Abou-Alfa GK, Cercek A, Harding JJ, Balachandran VP, Drebin JA, Allen PJ, Kingham TP, D'Angelica MI, Jarnagin WR (2019) Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. HPB (Oxford). https://doi.org/10.1016/j.hpb.2019.03.370 CrossRef

12.

Spolverato G, Kim Y, Alexandrescu S, Popescu I, Marques HP, Aldrighetti L, Clark Gamblin T, Miura J, Maithel SK, Squires MH, Pulitano C, Sandroussi C, Mentha G, Bauer TW, Newhook T, Shen F, Poultsides GA, Wallis Marsh J, Pawlik TM (2015) Is hepatic resection for large or multifocal intrahepatic cholangiocarcinoma justified? Results from a multiinstitutional collaboration. Ann Surg Oncol 22:2218. https://doi.org/10.1245/s10434-014-4223-3 CrossRefPubMed

13.

Nimura Y, Kamiya J, Nagino M, Kanai M, Uesaka K, Kondo S, Hayakawa N (1998) Aggressive surgical treatment of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 5:52. https://doi.org/10.1007/PL00009951 CrossRefPubMed

14.

Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y (2007) Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complication. World J Surg 31:1256. https://doi.org/10.1007/s00268-007-9001-y CrossRefPubMed

15.

Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689. https://doi.org/10.1002/cncr.11699 CrossRefPubMed

16.

Malhi H, Gores GJ (2006) Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45:856–867. https://doi.org/10.1016/j.jhep.2006.09.001 CrossRefPubMedPubMedCentral

17.

Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A (2014) Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5:2839–2852. https://doi.org/10.18632/oncotarget.1943 CrossRefPubMedPubMedCentral

18.

Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D'Onofrio M, Iacono C, Scarpa A, Guglielmi A (2015) Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol 23:1699–1707. https://doi.org/10.1245/s10434-015-5046-6 CrossRefPubMed

19.

Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T, Nakagawa H (2018) Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol 68:959–969. https://doi.org/10.1016/j.jhep.2018.01.009 CrossRefPubMed

20.

Raggi C, Invernizzi P, Andersen JB (2015) Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J Hepatol 62:198–207. https://doi.org/10.1016/j.jhep.2014.09.007 CrossRefPubMed

21.

Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini A, Malpeli G, Lawlor RT, Scarpa A (2013) DNA qualification workflow for next generation sequencing of histopathological samples. PLoS ONE 8(6):e62692. https://doi.org/10.1371/journal.pone.0062692 CrossRefPubMedPubMedCentral

22.

Zamo A, Bertolaso A, van Raaij AW, Mancini F, Scardoni M, Montresor M, Menestrina F, van Krieken JHJM, Chilosi M, Groenen PJTA, Scarpa A (2012) Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. J Mol Diagn 14(1):30–37. https://doi.org/10.1016/j.jmoldx.2011.07.007 CrossRefPubMed

23.

Zang X-F, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM (2018) Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 105:848–856. https://doi.org/10.1002/bjs.10676 CrossRef

24.

Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Masato N (2018) Recurrence after curative-intent resection of peri-hilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery 163(4):732–738. https://doi.org/10.1016/j.surg.2017.08.011 CrossRefPubMed

25.

Bagante F, Ruzzenente A, Conci S, Rusev BC, Simbolo M, Campagnaro T, Pawlik TM, Luchini C, Iacono C, Scarpa A, Guglielmi A (2019) Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? HPB (Oxford). https://doi.org/10.1016/j.hpb.2019.04.002 CrossRef

26.

Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, Mafficini A, Rusev B, Corbo V, Capelli P, Bria E, Pedron S, Turri G, Lawlor RT, Tortora G, Bassi C, Gugliemi A, Scarpa A (2018) Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep 8(1):7119. https://doi.org/10.1038/s41598-018-25669-1 CrossRefPubMedPubMedCentral

27.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL (2019) Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer 120(2):165–171. https://doi.org/10.1038/s41416-018-0334-0(Epub 2018 Nov 13) CrossRefPubMed

28.

Lowery MA, Abou-Alfa GK, Burris HA et al (2017) Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 35:4015CrossRef

29.

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1). ClinicalTrials.gov identifier (NCT number): NCT03875235

30.

A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy. ClinicalTrials.gov identifier (NCT number): NCT03833661

Title: Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients
Authors: Simone Conci
Andrea Ruzzenente
Michele Simbolo
Fabio Bagante
Borislav Rusev
Giulia Isa
Rita T. Lawlor
Corrado Pedrazzani
Calogero Iacono
Alfredo Guglielmi
Aldo Scarpa
Publication date: 01-03-2020
Publisher: Springer International Publishing
Keywords: Gallbladder Cancer
Gallbladder Cancer
Cholangiocarcinoma
Cholangiocarcinoma
Published in: Updates in Surgery / Issue 1/2020
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-020-00718-5

At a glance: The STEP trials

Springer Medicine

Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?

Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer

Retrograde tracing along “cystic duct” method to prevent biliary misidentification injury in laparoscopic cholecystectomy

Safety and efficacy of prophylactic resorbable biosynthetic mesh in loop-ileostomy reversal: a case–control study

Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste

Is follow-up still mandatory more than 5 years after surgery for colorectal cancer?